subscribeSubscribe
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept
PR NEWSWIRE
17 Apr 2023
Share Share
Lilly inks licensing deal for cancer therapy with Australian biotech Telix

Lilly inks licensing deal for cancer therapy with Australian biotech Telix
D. Lokuwithania SEEKING ALPHA
12 Apr 2022
Share Share
Lilly inks licensing deal for cancer therapy with Australian biotech Telix

Lilly inks licensing deal for cancer therapy with Australian biotech Telix
Dulan Lokuwithania SEEKING ALPHA
11 Apr 2022
Share Share
Keytruda is First to Add Indications Under TGA’s Provisional Approval Pathway

Keytruda is First to Add Indications Under TGA’s Provisional Approval Pathway
Zachary Brennan RAPS
18 Jul 2019
Share Share
Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behind

Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behind
Eric Sagonowsky FIERCE PHARMA
11 Jul 2019
Share Share
Suffering a series of setbacks, Eli Lilly’s oncology executes 2 of its top drugs

Suffering a series of setbacks, Eli Lilly’s oncology executes 2 of its top drugs
John Carroll ENDPTS
30 Apr 2019
Share Share
EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo

EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo
EMA
27 Apr 2019
Share Share
Eli Lilly to Pull Cancer Drug From Market After Failed Study

Eli Lilly to Pull Cancer Drug From Market After Failed Study
Andrew Dunn BIOPHARMADIVE
26 Apr 2019
Share Share
Eli Lilly aims to keep current Lartruvo patients as drug exits world stage

Eli Lilly aims to keep current Lartruvo patients as drug exits world stage
Kyle Blankenship FIERCE PHARMA
25 Apr 2019
Share Share
Eli Lilly backs U.S. proposal on drug rebates to lower costs

Eli Lilly backs U.S. proposal on drug rebates to lower costs
Tamara Mathias REUTERS
07 Feb 2019
Share Share